Trial Profile
A Phase II, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis With or Without Mesalamine [mesalazine].
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jul 2020
Price :
$35
*
At a glance
- Drugs HMPL 004 (Primary) ; Mesalazine
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 03 May 2012 EudraCT reports trial status as discontinued and inclusion-exclusion criteria amended.
- 28 Apr 2012 Additional trial location added as reported by European Clinical Trials Database.
- 28 Apr 2012 New source identified and integrated (EudraCT2007-005166-12: European Clinical Trials Database)